nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—ADRA2C—Class A/1 (Rhodopsin-like receptors)—RHO—age related macular degeneration	0.00574	0.00574	CbGpPWpGaD
Droxidopa—ADRA1B—Class A/1 (Rhodopsin-like receptors)—RHO—age related macular degeneration	0.00565	0.00565	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—SERPING1—age related macular degeneration	0.00558	0.00558	CbGpPWpGaD
Droxidopa—SLC6A2—Transmembrane transport of small molecules—ABCG4—age related macular degeneration	0.00557	0.00557	CbGpPWpGaD
Droxidopa—ADRA2A—GPCRs, Class A Rhodopsin-like—RHO—age related macular degeneration	0.00545	0.00545	CbGpPWpGaD
Droxidopa—DDC—Metabolism—ELOVL4—age related macular degeneration	0.00521	0.00521	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR ligand binding—RHO—age related macular degeneration	0.00519	0.00519	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—RAD51B—age related macular degeneration	0.00518	0.00518	CbGpPWpGaD
Droxidopa—ADRA1A—Class A/1 (Rhodopsin-like receptors)—RHO—age related macular degeneration	0.00502	0.00502	CbGpPWpGaD
Droxidopa—SLC6A2—Transmembrane transport of small molecules—ABCA4—age related macular degeneration	0.00496	0.00496	CbGpPWpGaD
Droxidopa—SLC6A2—Transmembrane transport of small molecules—SLC16A8—age related macular degeneration	0.00496	0.00496	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—RAD51B—age related macular degeneration	0.00484	0.00484	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—F13B—age related macular degeneration	0.00482	0.00482	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—SLC16A8—age related macular degeneration	0.00481	0.00481	CbGpPWpGaD
Droxidopa—ADRB1—GPCR ligand binding—RHO—age related macular degeneration	0.00473	0.00473	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR ligand binding—RHO—age related macular degeneration	0.00468	0.00468	CbGpPWpGaD
Droxidopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—RHO—age related macular degeneration	0.00467	0.00467	CbGpPWpGaD
Droxidopa—ADRB2—GPCR ligand binding—RHO—age related macular degeneration	0.00462	0.00462	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—SERPING1—age related macular degeneration	0.00453	0.00453	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—RHO—age related macular degeneration	0.0045	0.0045	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—SLC16A8—age related macular degeneration	0.0045	0.0045	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR ligand binding—RHO—age related macular degeneration	0.00437	0.00437	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR ligand binding—RHO—age related macular degeneration	0.00431	0.00431	CbGpPWpGaD
Droxidopa—PAH—Disease—CST3—age related macular degeneration	0.00421	0.00421	CbGpPWpGaD
Droxidopa—DDC—Metabolism—SLC16A8—age related macular degeneration	0.0042	0.0042	CbGpPWpGaD
Droxidopa—SLC16A10—Transmembrane transport of small molecules—CETP—age related macular degeneration	0.00411	0.00411	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—RHO—age related macular degeneration	0.00409	0.00409	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—RDH8—age related macular degeneration	0.00394	0.00394	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—RAD51B—age related macular degeneration	0.00393	0.00393	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—RHO—age related macular degeneration	0.00382	0.00382	CbGpPWpGaD
Droxidopa—PAH—Disease—TGFBR1—age related macular degeneration	0.00378	0.00378	CbGpPWpGaD
Droxidopa—DDC—SIDS Susceptibility Pathways—VEGFA—age related macular degeneration	0.00375	0.00375	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—SLC16A8—age related macular degeneration	0.00365	0.00365	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—RHO—age related macular degeneration	0.00355	0.00355	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—RPE65—age related macular degeneration	0.00344	0.00344	CbGpPWpGaD
Droxidopa—ADRB3—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00338	0.00338	CbGpPWpGaD
Droxidopa—PAH—Metabolism—LIPC—age related macular degeneration	0.00332	0.00332	CbGpPWpGaD
Droxidopa—PAH—Metabolism—CETP—age related macular degeneration	0.0032	0.0032	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—RHO—age related macular degeneration	0.00293	0.00293	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—ABCA4—age related macular degeneration	0.00277	0.00277	CbGpPWpGaD
Droxidopa—ADRA2B—Platelet activation, signaling and aggregation—CD36—age related macular degeneration	0.00277	0.00277	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—RHO—age related macular degeneration	0.00267	0.00267	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—RHO—age related macular degeneration	0.00266	0.00266	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—RHO—age related macular degeneration	0.00265	0.00265	CbGpPWpGaD
Droxidopa—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.00265	0.00265	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—RHO—age related macular degeneration	0.00261	0.00261	CbGpPWpGaD
Droxidopa—ADRA2C—Platelet activation, signaling and aggregation—CD36—age related macular degeneration	0.00259	0.00259	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—NMNAT1—age related macular degeneration	0.00259	0.00259	CbGpPWpGaD
Droxidopa—ADRB3—GPCR ligand binding—C3—age related macular degeneration	0.00257	0.00257	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—RDH8—age related macular degeneration	0.00257	0.00257	CbGpPWpGaD
Droxidopa—ADRA2B—G alpha (i) signalling events—C3—age related macular degeneration	0.0025	0.0025	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—RHO—age related macular degeneration	0.00247	0.00247	CbGpPWpGaD
Droxidopa—SLC6A2—Transmembrane transport of small molecules—CETP—age related macular degeneration	0.00245	0.00245	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—RHO—age related macular degeneration	0.00243	0.00243	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—RHO—age related macular degeneration	0.00243	0.00243	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—RHO—age related macular degeneration	0.00241	0.00241	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—RHO—age related macular degeneration	0.0024	0.0024	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—RHO—age related macular degeneration	0.00237	0.00237	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—RDH8—age related macular degeneration	0.00234	0.00234	CbGpPWpGaD
Droxidopa—ADRA2C—G alpha (i) signalling events—C3—age related macular degeneration	0.00234	0.00234	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—RDH8—age related macular degeneration	0.00232	0.00232	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—RDH8—age related macular degeneration	0.00229	0.00229	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—ELOVL4—age related macular degeneration	0.00226	0.00226	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—RHO—age related macular degeneration	0.00224	0.00224	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—RPE65—age related macular degeneration	0.00224	0.00224	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—RHO—age related macular degeneration	0.00221	0.00221	CbGpPWpGaD
Droxidopa—ADRA1D—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.0022	0.0022	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—RDH8—age related macular degeneration	0.00216	0.00216	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—RHO—age related macular degeneration	0.00216	0.00216	CbGpPWpGaD
Droxidopa—DDC—Metabolism—LIPC—age related macular degeneration	0.00215	0.00215	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—RDH8—age related macular degeneration	0.00213	0.00213	CbGpPWpGaD
Droxidopa—ADRA2A—Platelet activation, signaling and aggregation—CD36—age related macular degeneration	0.0021	0.0021	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—NMNAT1—age related macular degeneration	0.0021	0.0021	CbGpPWpGaD
Droxidopa—DDC—Metabolism—CETP—age related macular degeneration	0.00207	0.00207	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—RPE65—age related macular degeneration	0.00204	0.00204	CbGpPWpGaD
Droxidopa—PAH—Disease—APOE—age related macular degeneration	0.00203	0.00203	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—RPE65—age related macular degeneration	0.00202	0.00202	CbGpPWpGaD
Droxidopa—ADRB3—GPCR ligand binding—CCL2—age related macular degeneration	0.00201	0.00201	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—RHO—age related macular degeneration	0.00201	0.00201	CbGpPWpGaD
Droxidopa—ADRB1—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00201	0.00201	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—RPE65—age related macular degeneration	0.002	0.002	CbGpPWpGaD
Droxidopa—ADRA2B—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00199	0.00199	CbGpPWpGaD
Droxidopa—ADRB2—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00196	0.00196	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—RHO—age related macular degeneration	0.00196	0.00196	CbGpPWpGaD
Droxidopa—PAH—Metabolism—CD36—age related macular degeneration	0.00193	0.00193	CbGpPWpGaD
Droxidopa—ADRA2A—G alpha (i) signalling events—C3—age related macular degeneration	0.0019	0.0019	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—RDH8—age related macular degeneration	0.00189	0.00189	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—RPE65—age related macular degeneration	0.00189	0.00189	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—RPE65—age related macular degeneration	0.00186	0.00186	CbGpPWpGaD
Droxidopa—ADRA2C—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00186	0.00186	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—ELOVL4—age related macular degeneration	0.00184	0.00184	CbGpPWpGaD
Droxidopa—ADRA1B—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00183	0.00183	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—RHO—age related macular degeneration	0.00182	0.00182	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—SLC16A8—age related macular degeneration	0.00182	0.00182	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—ABCA4—age related macular degeneration	0.00181	0.00181	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—RDH8—age related macular degeneration	0.00176	0.00176	CbGpPWpGaD
Droxidopa—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.00172	0.00172	CbGpPWpGaD
Droxidopa—PAH—Metabolism—APOE—age related macular degeneration	0.0017	0.0017	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR ligand binding—C3—age related macular degeneration	0.00168	0.00168	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—RPE65—age related macular degeneration	0.00165	0.00165	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—ABCA4—age related macular degeneration	0.00165	0.00165	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—ABCA4—age related macular degeneration	0.00163	0.00163	CbGpPWpGaD
Droxidopa—ADRA1A—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00162	0.00162	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—ABCA4—age related macular degeneration	0.00161	0.00161	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—RHO—age related macular degeneration	0.00157	0.00157	CbGpPWpGaD
Droxidopa—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.00157	0.00157	CbGpPWpGaD
Droxidopa—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.00156	0.00156	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—RPE65—age related macular degeneration	0.00154	0.00154	CbGpPWpGaD
Droxidopa—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.00154	0.00154	CbGpPWpGaD
Droxidopa—ADRB1—GPCR ligand binding—C3—age related macular degeneration	0.00153	0.00153	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—ABCA4—age related macular degeneration	0.00152	0.00152	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR ligand binding—C3—age related macular degeneration	0.00151	0.00151	CbGpPWpGaD
Droxidopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—C3—age related macular degeneration	0.00151	0.00151	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—ABCA4—age related macular degeneration	0.0015	0.0015	CbGpPWpGaD
Droxidopa—ADRB2—GPCR ligand binding—C3—age related macular degeneration	0.00149	0.00149	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—SLC16A8—age related macular degeneration	0.00148	0.00148	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—C3—age related macular degeneration	0.00145	0.00145	CbGpPWpGaD
Droxidopa—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.00145	0.00145	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—RHO—age related macular degeneration	0.00143	0.00143	CbGpPWpGaD
Droxidopa—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.00143	0.00143	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—CD36—age related macular degeneration	0.00143	0.00143	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—RHO—age related macular degeneration	0.00142	0.00142	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR ligand binding—C3—age related macular degeneration	0.00141	0.00141	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—RHO—age related macular degeneration	0.0014	0.0014	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR ligand binding—C3—age related macular degeneration	0.00139	0.00139	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—TGFBR1—age related macular degeneration	0.00136	0.00136	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—CD36—age related macular degeneration	0.00133	0.00133	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ABCA4—age related macular degeneration	0.00133	0.00133	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—RHO—age related macular degeneration	0.00133	0.00133	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—C3—age related macular degeneration	0.00132	0.00132	CbGpPWpGaD
Droxidopa—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—age related macular degeneration	0.00132	0.00132	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR ligand binding—CCL2—age related macular degeneration	0.00131	0.00131	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—RHO—age related macular degeneration	0.00131	0.00131	CbGpPWpGaD
Droxidopa—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.00127	0.00127	CbGpPWpGaD
Droxidopa—DDC—Metabolism—CD36—age related macular degeneration	0.00125	0.00125	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ABCA4—age related macular degeneration	0.00124	0.00124	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—C3—age related macular degeneration	0.00124	0.00124	CbGpPWpGaD
Droxidopa—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—age related macular degeneration	0.00123	0.00123	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—SQSTM1—age related macular degeneration	0.00123	0.00123	CbGpPWpGaD
Droxidopa—ADRB1—GPCR ligand binding—CCL2—age related macular degeneration	0.0012	0.0012	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR ligand binding—CCL2—age related macular degeneration	0.00118	0.00118	CbGpPWpGaD
Droxidopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—age related macular degeneration	0.00118	0.00118	CbGpPWpGaD
Droxidopa—ADRB2—GPCR ligand binding—CCL2—age related macular degeneration	0.00117	0.00117	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—RHO—age related macular degeneration	0.00116	0.00116	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—C3—age related macular degeneration	0.00115	0.00115	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR ligand binding—CCL2—age related macular degeneration	0.00111	0.00111	CbGpPWpGaD
Droxidopa—DDC—Metabolism—APOE—age related macular degeneration	0.0011	0.0011	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR ligand binding—CCL2—age related macular degeneration	0.00109	0.00109	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—CD36—age related macular degeneration	0.00108	0.00108	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—RHO—age related macular degeneration	0.00108	0.00108	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—CCL2—age related macular degeneration	0.00103	0.00103	CbGpPWpGaD
Droxidopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—age related macular degeneration	0.001	0.001	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—CCL2—age related macular degeneration	0.000967	0.000967	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—C3—age related macular degeneration	0.000948	0.000948	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—LIPC—age related macular degeneration	0.000933	0.000933	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—CETP—age related macular degeneration	0.0009	0.0009	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—CCL2—age related macular degeneration	0.000899	0.000899	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TGFBR1—age related macular degeneration	0.000883	0.000883	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—C3—age related macular degeneration	0.000864	0.000864	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—C3—age related macular degeneration	0.000861	0.000861	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—C3—age related macular degeneration	0.000856	0.000856	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—C3—age related macular degeneration	0.000845	0.000845	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TGFBR1—age related macular degeneration	0.000804	0.000804	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—SQSTM1—age related macular degeneration	0.0008	0.0008	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—C3—age related macular degeneration	0.000799	0.000799	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TGFBR1—age related macular degeneration	0.000797	0.000797	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TGFBR1—age related macular degeneration	0.000787	0.000787	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—C3—age related macular degeneration	0.000787	0.000787	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—C3—age related macular degeneration	0.000784	0.000784	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—C3—age related macular degeneration	0.00078	0.00078	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—C3—age related macular degeneration	0.000777	0.000777	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—C3—age related macular degeneration	0.000767	0.000767	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—LIPC—age related macular degeneration	0.000758	0.000758	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TGFBR1—age related macular degeneration	0.000744	0.000744	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TGFBR1—age related macular degeneration	0.000733	0.000733	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CETP—age related macular degeneration	0.000731	0.000731	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—SQSTM1—age related macular degeneration	0.000729	0.000729	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—APOE—age related macular degeneration	0.000727	0.000727	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—C3—age related macular degeneration	0.000726	0.000726	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—SQSTM1—age related macular degeneration	0.000723	0.000723	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—C3—age related macular degeneration	0.000714	0.000714	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—SQSTM1—age related macular degeneration	0.000713	0.000713	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—KDR—age related macular degeneration	0.000712	0.000712	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—C3—age related macular degeneration	0.000699	0.000699	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—VEGFA—age related macular degeneration	0.00068	0.00068	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—SQSTM1—age related macular degeneration	0.000675	0.000675	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—CCL2—age related macular degeneration	0.000673	0.000673	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—SQSTM1—age related macular degeneration	0.000664	0.000664	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TGFBR1—age related macular degeneration	0.000651	0.000651	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—C3—age related macular degeneration	0.000649	0.000649	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—VEGFA—age related macular degeneration	0.000635	0.000635	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—C3—age related macular degeneration	0.000634	0.000634	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—CCL2—age related macular degeneration	0.000614	0.000614	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CCL2—age related macular degeneration	0.000611	0.000611	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—CCL2—age related macular degeneration	0.000608	0.000608	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TGFBR1—age related macular degeneration	0.000605	0.000605	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—CCL2—age related macular degeneration	0.0006	0.0006	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—SQSTM1—age related macular degeneration	0.00059	0.00059	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—C3—age related macular degeneration	0.00059	0.00059	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—CCL2—age related macular degeneration	0.000568	0.000568	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—CCL2—age related macular degeneration	0.000559	0.000559	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—SQSTM1—age related macular degeneration	0.000548	0.000548	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—CD36—age related macular degeneration	0.000541	0.000541	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—VEGFA—age related macular degeneration	0.000516	0.000516	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—C3—age related macular degeneration	0.000508	0.000508	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—CCL2—age related macular degeneration	0.000497	0.000497	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—APOE—age related macular degeneration	0.000477	0.000477	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—APOE—age related macular degeneration	0.000473	0.000473	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—KDR—age related macular degeneration	0.000464	0.000464	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—C3—age related macular degeneration	0.000463	0.000463	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—CCL2—age related macular degeneration	0.000461	0.000461	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—C3—age related macular degeneration	0.000459	0.000459	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—C3—age related macular degeneration	0.000453	0.000453	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CD36—age related macular degeneration	0.00044	0.00044	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—APOE—age related macular degeneration	0.000431	0.000431	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—C3—age related macular degeneration	0.000429	0.000429	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—APOE—age related macular degeneration	0.000427	0.000427	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—KDR—age related macular degeneration	0.000423	0.000423	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—C3—age related macular degeneration	0.000422	0.000422	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—APOE—age related macular degeneration	0.000422	0.000422	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—KDR—age related macular degeneration	0.000419	0.000419	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—KDR—age related macular degeneration	0.000413	0.000413	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—APOE—age related macular degeneration	0.000399	0.000399	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CCL2—age related macular degeneration	0.000398	0.000398	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—APOE—age related macular degeneration	0.000393	0.000393	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—VEGFA—age related macular degeneration	0.000392	0.000392	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—KDR—age related macular degeneration	0.000391	0.000391	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—APOE—age related macular degeneration	0.000388	0.000388	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—KDR—age related macular degeneration	0.000385	0.000385	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—C3—age related macular degeneration	0.000375	0.000375	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CCL2—age related macular degeneration	0.000362	0.000362	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CCL2—age related macular degeneration	0.000359	0.000359	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CCL2—age related macular degeneration	0.000355	0.000355	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—APOE—age related macular degeneration	0.000349	0.000349	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—C3—age related macular degeneration	0.000348	0.000348	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—KDR—age related macular degeneration	0.000342	0.000342	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CCL2—age related macular degeneration	0.000336	0.000336	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CCL2—age related macular degeneration	0.00033	0.00033	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—APOE—age related macular degeneration	0.000324	0.000324	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—KDR—age related macular degeneration	0.000318	0.000318	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CCL2—age related macular degeneration	0.000293	0.000293	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CCL2—age related macular degeneration	0.000273	0.000273	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—VEGFA—age related macular degeneration	0.000255	0.000255	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—VEGFA—age related macular degeneration	0.000233	0.000233	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—VEGFA—age related macular degeneration	0.000231	0.000231	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—VEGFA—age related macular degeneration	0.000228	0.000228	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—VEGFA—age related macular degeneration	0.000215	0.000215	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—VEGFA—age related macular degeneration	0.000212	0.000212	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—VEGFA—age related macular degeneration	0.000188	0.000188	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—VEGFA—age related macular degeneration	0.000175	0.000175	CbGpPWpGaD
